In this issue:
Proposed definitions of typical lesions in HS
There is a significant association between HS and IBD
Clinical benefits observed with the use of pre-surgical ultrasound HS lesion assessment
Epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life in HS
Ustekinumab may be option for HS patients who do not respond to front-line adalimumab treatment
Bacterial translocation may contribute to the pathogenesis of HS
There is an unmet need for weight counselling in paediatric HS patients
Fecal calprotectin may be a biomarker of disease activity in HS
Two surgical methods - excision and deroofing – are low resource options for the outpatient setting
Intralesional triamcinolone is not efficacious for acute HS lesions
Please login below to download this issue (PDF)